Business Context and Reporting Period
This Form 8-K, dated May 14, 2026, reports on Neurocrine Biosciences, Inc. (the "Company"). The filing details the completion of a tender offer and subsequent merger to acquire Soleno Therapeutics, Inc. ("Soleno"), as well as the establishment of a new credit facility. The tender offer expired on May 15, 2026, and the merger was consummated on May 18, 2026.
Key Financial Metrics and Transaction Details
- Acquisition Cost: The aggregate cash paid for the Soleno acquisition was approximately $2.9 billion, plus related fees and expenses.
- Offer Price: $53.00 per Soleno share in cash.
- Tender Results: 46,356,114 Soleno shares were validly tendered, representing approximately 88.9% of outstanding shares.
- Financing: The Company entered into a $1.0 billion senior secured revolving credit facility on May 14, 2026.
- Initial Borrowing: $600.0 million was borrowed under the new facility on the closing date.
- Funding Source: The acquisition was funded by available cash on hand.
- Debt Covenants: Maximum total net leverage ratio of 3.75:1.00 (potentially 4.25:1.00 post-acquisition) and minimum consolidated interest coverage ratio of 2.00:1.00.
Material Changes
The primary material change is the acquisition of Soleno Therapeutics, Inc., which became a direct wholly-owned subsidiary of Neurocrine. The transaction involved the conversion of all outstanding Soleno shares, options, and restricted stock units into cash payments based on the $53.00 offer price. Additionally, the Company's capital structure changed with the incurrence of a new $1.0 billion revolving credit facility and an immediate $600 million drawdown.
Outlook, Risks, and Contingencies
- Pro Forma Information: The Company intends to file required pro forma financial information and financial statements of the acquired business within 71 calendar days of this report.
- Employee Compensation: Cash payments for Soleno options and RSUs will be made within 15 days of the effective time of the merger.
- Security Interest: The Company granted a security interest in substantially all of its assets to secure the new credit facility.
- Appraisal Rights: Soleno shareholders who properly exercised appraisal rights did not receive the offer price and are subject to Delaware General Corporation Law procedures.
Investor Verification Checklist
- Verify the final aggregate consideration paid, including any adjustments for fees and expenses beyond the stated $2.9 billion.
- Review the upcoming pro forma financial statements (due within 71 days) to assess the impact of the acquisition on Neurocrine's liquidity and leverage ratios.
- Confirm the specific terms of the $1.0 billion credit facility, particularly the variable interest rate margins and commitment fees.
- Monitor the Company's compliance with the new financial covenants (3.75:1.00 leverage ratio) in the post-merger period.
- Check for any subsequent filings regarding the resolution of appraisal rights or dissenting shareholders.